InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
60,682.14
(
-0.34%
)
Post# of 252431
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119956
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 3628

Tuesday, 09/21/2004 3:52:51 AM

Tuesday, September 21, 2004 3:52:51 AM

Post# of 252431
Another development on the transgenics front:

http://yahoo.reuters.com/financeQuoteCompanyNewsArticle.jhtml?duid=mtfh66069_2004-09-20_19-27-38_n20...

>>
Nexia Biotech gets lift from Canadian defense deal

Mon Sep 20, 2004 03:27 PM ET

OTTAWA, Sept 20 (Reuters) - Shares in Nexia Biotechnologies Inc. (NXB.TO:) added 11 percent on Monday after the company announced a three-year deal with Canada's defense department to speed development of its Protexia antidote for nerve agents.

Defence R&D Canada will spend C$2 million ($1.55 million) to study how Protexia, derived from genetically altered goat's milk, performs in various types of chemical weapon exposure.

Researchers will examine how Protexia works when it is given before or after nerve gas is encountered, and how it interacts in combination with other therapies, such as oximes, which essentially kick-start the nervous system.

Protexia has been shown to protect animals from the toxic effects of multiple lethal exposures to a broad spectrum of chemical agents. Further research and testing on animals is required before the protein can be tested for human use.

The product is a naturally occurring protein found in human blood in minute quantities.

Data from the study will be used in Nexia's investigational new drug filing with the U.S. Food and Drug Administration, which chief executive Jeffrey Turner said is planned for late 2005 or early 2006.

The so-called counter-terrorism antidote falls under an animal efficacy rule, which requires the proof of safety in humans and efficacy in animals, Turner said.

Normally, proof of both safety and efficacy in humans is required, a more lengthy application process.

Shares in Nexia rose to C$1.20 on the Toronto Stock Exchange after the news, still well off their year high of C$2.10.
<<

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up